Literature DB >> 19390547

Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.

Ursina R Teitelbaum1, Daniel G Haller.   

Abstract

In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19390547     DOI： 10.1038/nrclinonc.2009.46

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  6 in total

1.  Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

Authors:  Hans-Joachim Schmoll; Thomas Cartwright; Josep Tabernero; Marek P Nowacki; Arie Figer; Jean Maroun; Timothy Price; Robert Lim; Eric Van Cutsem; Young-Suk Park; Joseph McKendrick; Claire Topham; Gemma Soler-Gonzalez; Filipo de Braud; Mark Hill; Florin Sirzén; Daniel G Haller
Journal:  J Clin Oncol       Date:  2007-01-01       Impact factor: 44.544

2.  Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

Authors:  Hendrik-Tobias Arkenau; Ullrich Graeven; Stephan Kubicka; Axel Grothey; Christina Englisch-Fritz; Albrecht Kretzschmar; Richard Greil; Werner Freier; Thomas Seufferlein; Axel Hinke; Hans-Joachim Schmoll; Wolff Schmiegel; Rainer Porschen
Journal:  Clin Colorectal Cancer       Date:  2008-01       Impact factor: 4.481

3.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Authors:  Jim Cassidy; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Leonard Saltz
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

4.  Potential regional differences for the tolerability profiles of fluoropyrimidines.

Authors:  Daniel G Haller; Jim Cassidy; Stephen J Clarke; David Cunningham; Eric Van Cutsem; Paulo M Hoff; Mace L Rothenberg; Leonard B Saltz; Hans-Joachim Schmoll; Carmen Allegra; Joseph R Bertino; Jean-Yves Douillard; Bengt G Gustavsson; Gerard Milano; Michael O'Connell; Youcef Rustum; Josep Tabernero; Frank Gilberg; Florin Sirzén; Chris Twelves
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

5.  Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Authors:  Hendrik-Tobias Arkenau; Dirk Arnold; Jim Cassidy; Eduardo Diaz-Rubio; Jean-Yves Douillard; Howard Hochster; Andrea Martoni; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll; Rainer Porschen
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

6.  Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.

Authors:  M L Rothenberg; J V Cox; C Butts; M Navarro; Y-J Bang; R Goel; S Gollins; L L Siu; S Laguerre; D Cunningham
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.